Magenta Therapeutics Announces Updated Phase 2 Data on MGTA-456 Cell Therapy, Demonstrating Continued Durability in Inherited Metabolic Disorders
(World News Science)

PDF Version -- Additional data from Phase 2 study show that MGTA-456 demonstrates clinically meaningful durable benefits for patients with inherited metabolic disorders one year following treatment - -- Magenta intends to complete enrollment in Phase 2 in 2020 and continue dialogue with the FDA under the RMAT designation on design of a registration-enabling study, and to have discussions with the European Medicines Agency for development in Europe as well - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 20, 2020-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced...